Your browser doesn't support javascript.
loading
Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicentre retrospective case-control study.
Culerrier, Julien; Nguyen, Yann; Karadag, Omer; Yasar Bilge, Sule; Yildrim, Tuba Demirci; Ögüt, Tahir Saygin; Yazisiz, Veli; Bes, Cemal; Celfe, Ayse; Yazici, Ayten; Sadioglu Cagdas, Oznur; Kronbichler, Andreas; Jayne, David; Gauckler, Philipp; Regent, Alexis; Teixeira, Vitor; Marchand-Adam, Sylvain; Duffau, Pierre; Housz-Oro, Saskia Ingen-; Droumaguet, Celine; Andre, Baptiste; Luca, Luminita; Lechtman, Sarah; Aouba, Achille; Lebas, Celine; Servettaz, Amélie; Dernoncourt, Amandine; Ruivard, Marc; Milesi, Anne-Marie; Poindron, Vincent; Jego, Patrick; Padoan, Roberto; Delvino, Paolo; Vandergheynst, Frédéric; Pagnoux, Christian; Yacyshyn, Elaine; Lamprecht, Peter; Flossmann, Oliver; Puéchal, Xavier; Terrier, Benjamin.
Afiliación
  • Culerrier J; Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France.
  • Nguyen Y; Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France.
  • Karadag O; Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey.
  • Yasar Bilge S; Division of Rheumatology, Department of Internal Medicine, Vasculitis Research Center, Hacettepe University School of Medicine, Ankara, Turkey.
  • Yildrim TD; Department of Rheumatology, Dokuz Eylül University, Izmir, Turkey.
  • Ögüt TS; Department of Internal Medicine, Akdeniz University, Antalya, Turkey.
  • Yazisiz V; Department of Internal Medicine, Akdeniz University, Antalya, Turkey.
  • Bes C; Department of Internal Medicine, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
  • Celfe A; Department of Internal Medicine, Kocaeli University, Izmit, Turkey.
  • Yazici A; Department of Internal Medicine, Kocaeli University, Izmit, Turkey.
  • Sadioglu Cagdas O; Department of Internal Medicine, Kafkas University Medical Faculty, Kars, Turkey.
  • Kronbichler A; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Jayne D; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Gauckler P; Department of Internal Medicine, Medical University of Innsbruck, Austria.
  • Regent A; Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France.
  • Teixeira V; Department of Rheumatology, Faro Hospital, Faro, Portugal.
  • Marchand-Adam S; Department of Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France.
  • Duffau P; Department of Internal Medicine, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
  • Housz-Oro SI; Department of Dermatology, Hôpital Henri Mondor, AP-HP, Créteil, France.
  • Droumaguet C; Department of Internal Medicine, Hôpital Henri-Mondor, AP-HP, Créteil, France.
  • Andre B; Department of Internal Medicine, Centre Hospitalier Universitaire de La Timone, Marseille, France.
  • Luca L; Department of Internal Medicine, Hôpital de Poitiers, Poitiers, France.
  • Lechtman S; Department of Internal Medicine, Hôpital Lariboisière, AP-HP, Paris, France.
  • Aouba A; Department of Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France.
  • Lebas C; Department of Nephrology, Centre Hospitalier Universitaire de Lille, Lille, France.
  • Servettaz A; Department of Internal Medicine, Centre Hospitalier Universitaire de Reims, Reims, France.
  • Dernoncourt A; Department of Internal Medicine, Centre Hospitalier Universitaire d'Amiens-Picardie, Amiens, France.
  • Ruivard M; Department of Internal Medicine, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.
  • Milesi AM; Department of Internal Medicine, Centre Hospitalier de Vichy, Vichy, France.
  • Poindron V; Department of Internal Medicine, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.
  • Jego P; Department of Internal Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.
  • Padoan R; Department of Rheumatology, University of Padova, Padoue, Italy.
  • Delvino P; Department of Rheumatology, University of Pavia, Pavie, Italy.
  • Vandergheynst F; Department of Internal Medicine, Hôpital Erasme, Bruxelles, Belgique.
  • Pagnoux C; Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
  • Yacyshyn E; Department of Rheumatology, University of Alberta, Edmonton, Alberta, Canada.
  • Lamprecht P; Department of Rheumatology & Clinical Immunology, University of Luebeck, Lübeck, Germany.
  • Flossmann O; Department of Nephrology, Royal Berkshire Hospital, Reading, UK.
  • Puéchal X; Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France.
  • Terrier B; Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France.
Rheumatology (Oxford) ; 63(4): 999-1006, 2024 Apr 02.
Article en En | MEDLINE | ID: mdl-37354498
ABSTRACT

OBJECTIVE:

Data on ANCA-associated vasculitis (AAV) induced by anti-thyroid drugs (ATD) are scarce. We aimed to describe the characteristics and outcome of these patients in comparison to primary AAV.

METHODS:

We performed a retrospective multicentre study including patients with ATD-induced AAV. We focused on ATD-induced microscopic polyangiitis (MPA) and compared them with primary MPA by matching each case with four controls by gender and year of diagnosis.

RESULTS:

Forty-five patients with ATD-induced AAV of whom 24 MPA were included. ANCA were positive in 44 patients (98%), including myeloperoxidase (MPO)-ANCA in 21 (47%), proteinase 3 (PR3)-ANCA in six (13%), and double positive MPO- and PR3-ANCA in 15 (33%). Main clinical manifestations were skin involvement (64%), arthralgia (51%) and glomerulonephritis (20%). ATD was discontinued in 98% of cases, allowing vasculitis remission in seven (16%). All the remaining patients achieved remission after glucocorticoids, in combination with rituximab in 11 (30%) or cyclophosphamide in four (11%). ATD were reintroduced in seven cases (16%) without any subsequent relapse. Compared with 96 matched primary MPA, ATD-induced MPA were younger at diagnosis (48 vs 65 years, P < 0.001), had more frequent cutaneous involvement (54 vs 25%, P = 0.007), but less frequent kidney (38 vs 73%, P = 0.02), and a lower risk of relapse (adjusted HR 0.07; 95% CI 0.01, 0.65, P = 0.019).

CONCLUSION:

ATD-induced AAV were mainly MPA with MPO-ANCA, but double MPO- and PR3-ANCA positivity was frequent. The most common manifestations were skin and musculoskeletal manifestations. ATD-induced MPA were less severe and showed a lower risk of relapse than primary MPA.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Granulomatosis con Poliangitis / Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos / Poliangitis Microscópica Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Granulomatosis con Poliangitis / Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos / Poliangitis Microscópica Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Francia